Bodybuilding Health+ Review

Bodybuilding Health+ is the consumer telehealth program at bbhealthplus.com, not the Bodybuilding.com retail store. The current terms identify Dynamo Group LLC as the platform operator. Florida's official corporation record lists Dynamo Group, LLC as an active Delaware foreign LLC with its principal address at 1 Town Center Road, Suite 675, Boca Raton, Florida.

Dynamo Group states that it is not the medical practice, prescriber, manufacturer, or dispensing pharmacy. Independent medical entities and providers evaluate patients and make treatment decisions. Independent pharmacies fill approved prescriptions. Payment and intake do not guarantee that a prescription will be issued.

The home-page FAQ names Lion MD and physician leaders Ana Lisa Carr, MD, and Kelly Tenbrink, MD. Current NPPES records show active individual NPIs for both physicians. NPPES supports identity and taxonomy checks, not a claim that either doctor will treat every patient or holds an unverified board certification.

The same FAQ names Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx. Their current first-party sites and government records corroborate the published business identities. The terms still allow pharmacy assignment to vary, and a patient's prescription label controls the actual dispenser, formulation, concentration, quantity, and directions.

The public process begins with an online assessment, followed by licensed-provider review, a prescription decision, pharmacy fulfillment when approved, and ongoing check-ins. The visible intake initially requests height and weight. No patient information was submitted during research. The site does not promise one review time or one synchronous or asynchronous consultation format.

The home-page FAQ says the platform supports care in all fifty states. The legal terms say services are available in certain states and advise users to contact support for current availability. This review therefore does not claim that every treatment is available nationwide. Eligibility depends on the product, patient location, provider licensure, pharmacy reach, and current regulation.

The normalized section contains only four exact current catalog relationships: compounded semaglutide injection, compounded tirzepatide injection, compounded subcutaneous sermorelin, and oral tadalafil. Marketing names, treatment bundles, routes, and combination formulas do not become additional therapies.

The current GLP-1 selector lists semaglutide at $179 for one month, $478 for three months, $948 for six months, or $1,698 for twelve months. It lists tirzepatide at $209, $537, $1,048, or $2,248 for those terms. Older current first-party snapshots and lower sections on the same site show different monthly schedules. Both cards use the current one-month selector rate and remain outside direct price ranking.

Current promotional language also conflicts. The GLP-1 page advertises $100 off, while the public intake advertises $150 off the first month. AllyRx has an issued affiliate tracking URL, but neither discount has been verified for affiliate traffic, eligibility, renewal, or the selected plan. The CTA therefore uses the tracking link without a promotion.

The sermorelin page separates a subcutaneous injection from an oral dissolving tablet. Injection is $159 for one month or $497 billed once for three months. Oral treatment is $119 for one month or $297 billed once for three months. Lower cards on the same page separately say $129 first month for both, so only the injection's one-month selector price appears in the normalized card.

Daily tadalafil has four comparable standard terms: $115 for one month, $297 for three months, $534 for six months, and $948 for twelve months. Their plan-level monthly rates are $115, $99, $89, and $79. The unweighted mean is $95.50 and the compact card displays Avg. $96/mo. The exact total and commitment still depend on the selected term.

The sexual-health page also sells tadalafil with caffeine and L-citrulline and a tadalafil plus sildenafil formula. Those combinations have separate prices and ingredient identities and are not mapped to standalone tadalafil or sildenafil records. The same rule keeps NAD+ nasal spray, unresolved-route NAD+ injection, unresolved-route glutathione injection, GHK-Cu topical, and unspecified compounded PT-141 outside the comparison cards.

The platform is cash pay, and the terms say affiliated medical entities are not contracted with health insurance plans. No universal laboratory requirement, included panel, cash price, insurance pathway, or turnaround time is public. A clinician may still decide that testing or outside care is necessary for an individual patient.

The site says there is no monthly membership, no hidden fee, and that plans can be changed or cancelled through support. The legal terms provide the harder limits: medical consultation fees are nonrefundable, prescription products are final sale, and no treatment-plan notice cutoff is stated. The terms also contain mandatory arbitration, class and jury waivers, and a thirty-day opt-out procedure.

Discreet delivery is advertised, but the platform does not guarantee delivery time and disclaims independent pharmacy and carrier delays. No public shipping fee, transit estimate, temperature standard, damaged-order window, or replacement procedure was verified. Injectable GLP-1 users should follow the pharmacy label and contact the dispenser if a temperature-sensitive shipment arrives warm or delayed.

Most highlighted treatments are compounded. FDA states that compounded drugs are not FDA approved and do not receive premarket review for safety, effectiveness, or quality. Marketing language about an FDA-registered pharmacy must not be read as FDA approval of a pharmacy or product. The patient-specific prescription and pharmacy label are the controlling records.

The privacy policy says the platform collects account, payment, health, device, and activity information and may share information with providers, pharmacies, and service partners. It also describes audience use of hashed or de-identified data with Google and Meta. Users who care about marketing use should read the current privacy choices before submitting sensitive health details.